

# Giovanni Cammarota

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4132145/publications.pdf>

Version: 2024-02-01

362  
papers

14,725  
citations

23879

60  
h-index

29333

108  
g-index

366  
all docs

366  
docs citations

366  
times ranked

15725  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of gut microbiome on immunotherapy efficacy in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	12
2	Evaluating Donor Microbiome Before Fecal Microbiota Transplantation. <i>Gastroenterology</i> , 2022, 162, 993-994.	0.6	3
3	Fecal Microbiota Transplantation for Severe or Fulminant <i>Clostridioides difficile</i> Infection: Systematic Review and Meta-analysis. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, e1-e11.	0.1	14
4	Fecal Microbiota Transplantation in Children. , 2022, , 709-712.		0
5	How the gut parasitome affects human health. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210915.	1.4	19
6	Rummeliibacillus suwonensis: First Time Isolation from Human Feces by Culturomics. <i>Current Microbiology</i> , 2022, 79, .	1.0	0
7	Risk Factors, Diagnosis, and Management of <i>Clostridioides difficile</i> Infection in Patients with Inflammatory Bowel Disease. <i>Microorganisms</i> , 2022, 10, 1315.	1.6	7
8	Fecal Microbiota Transplantation Is Safe and Effective in Patients With <i>Clostridioides difficile</i> Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1627-1634.	2.4	24
9	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. <i>United European Gastroenterology Journal</i> , 2021, 9, 229-247.	1.6	66
10	Autologous faecal microbiota transplantation for type 1 diabetes: a potential mindshift in therapeutic microbiome manipulation?. <i>Gut</i> , 2021, 70, 2-3.	6.1	45
11	Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 599-622.	1.4	41
12	Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1360-1361.	0.2	2
13	&lt;i>&lt;i>Clostridioides difficile&lt;/i&lt;/i> infection during the COVID-19 pandemic: a gut microbiota&quot;based relationship. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 116-117.	0.3	2
14	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. <i>Nature Communications</i> , 2021, 12, 1926.	5.8	22
15	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	3.7	5
16	Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. <i>Digestive and Liver Disease</i> , 2021, 53, 1428-1432.	0.4	10
17	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 2605.	1.0	12
18	Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. <i>Digestive and Liver Disease</i> , 2021, 53, 1527-1528.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110258.	2.5	52
20	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100181.	3.0	43
21	Residual Gastrointestinal Symptoms after Fecal Microbiota Transplantation for <i>Clostridioides difficile</i> Infection: A Matter of Efficacy Rather Than Safety?. <i>Gastroenterology</i> , 2021, 161, 1344.	0.6	0
22	Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 33-42.	1.9	115
23	Improved gut microbiota features after the resolution of SARS-CoV-2 infection. <i>Gut Pathogens</i> , 2021, 13, 62.	1.6	10
24	Fecal Microbiome Transplantation for Recurrent <i>Clostridioides difficile</i> Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 470-476.	0.5	3
25	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.	1.4	37
26	Fecal microbiota transplantation for recurrent <i>C. difficile</i> infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. <i>Gut Microbes</i> , 2021, 13, 1994834.	4.3	21
27	COVID-19 in celiac disease: a multicentric retrospective cohort study. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 4400-4404.	0.5	5
28	How to define a quadruple aim framework to assess value in critical pathway of the patients with <i>Clostridioides difficile</i> infection. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 4597-4610.	0.5	2
29	Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 5826-5835.	0.5	1
30	The Italian National Faecal Microbiota Transplantation Program: a coordinated effort against <i>Clostridioides difficile</i> infection. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2021, 57, 239-243.	0.2	1
31	Laboratory handling practice for faecal microbiota transplantation. <i>Journal of Applied Microbiology</i> , 2020, 128, 893-898.	1.4	7
32	&lt;p&gt;Treatment of Recurrent &lt;em&gt; <i>Clostridioides difficile</i> &lt;/em&gt; Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease&lt;/p&gt;. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 563-570.	1.6	9
33	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	1.9	9
34	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for <i>C. difficile</i> infection during the COVID-19 pandemic: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2020, 52, 1390-1395.	0.4	16
35	Increased <i>Faecalibacterium</i> abundance is associated with clinical improvement in patients receiving rifaximin treatment. <i>Beneficial Microbes</i> , 2020, 11, 519-525.	1.0	13
36	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1306-1314.	0.9	35

#	ARTICLE	IF	CITATIONS
37	Letter: faecal microbiota transplantation for irritable bowel syndrome—room for improvement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 923-924.	1.9	7
38	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. <i>Future Microbiology</i> , 2020, 15, 1173-1183.	1.0	18
39	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	5.8	82
40	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231789.	1.1	58
41	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of <i>Akkermansia muciniphila</i> . <i>Digestive and Liver Disease</i> , 2020, 52, 1002-1010.	0.4	23
42	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. <i>Journal of Clinical Medicine</i> , 2020, 9, 1757.	1.0	65
43	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 430-432.	3.7	108
44	Gut microbiome, big data and machine learning to promote precision medicine for cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 635-648.	8.2	172
45	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	6.1	110
46	Fecal transplantation for ulcerative colitis: current evidence and future applications. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 343-351.	1.4	29
47	Fecal calprotectin and need of multiple microbiota transplantation infusions in <i>Clostridium difficile</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1909-1915.	1.4	5
48	Microbiome: what intensivists should know. <i>Minerva Anestesiologica</i> , 2020, 86, 777-785.	0.6	11
49	Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 48-69.	2.2	3
50	OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE. <i>Digestive and Liver Disease</i> , 2019, 51, e90.	0.4	0
51	Letter: improvement of clinical outcomes by metformin in metabolic liver disease—a microbiota-dependent mechanism?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 474-474.	1.9	0
52	Fecal microbiota transplant for <i>C. difficile</i> infection: Just say yes. <i>Anaerobe</i> , 2019, 60, 102109.	1.0	8
53	OC.11.4 CHARACTERIZATION OF ESOPHAGEAL MICROBIOTA IN PATIENTS WITH BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA. <i>Digestive and Liver Disease</i> , 2019, 51, e107.	0.4	0
54	FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 1021.	1.1	48

#	ARTICLE	IF	CITATIONS
55	Gut microbiome beats two to zero host genome. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 378-380.	0.7	1
56	OC.03.4 DECREASE OF BLOODSTREAM INFECTION RATES IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION TREATED WITH FAECAL MICROBIOTA TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e84-e85.	0.4	0
57	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 501.	1.8	39
58	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 240-248.	1.9	144
59	Emerging drugs for the treatment of clostridium difficile. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 17-28.	1.0	11
60	P128 Histological activity predicts clinical relapse in patients with ulcerative colitis in endoscopic remission. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S152-S152.	0.6	2
61	FMT for ulcerative colitis: closer to the turning point. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 266-268.	8.2	18
62	A Durum Wheat Variety-Based Product Is Effective in Reducing Symptoms in Patients with Non-Celiac Gluten Sensitivity: A Double-Blind Randomized Cross-Over Trial. <i>Nutrients</i> , 2019, 11, 712.	1.7	13
63	Impact evaluation of a Critical Pathway for patients with Clostridium difficile infection: A pre-post analysis in a Third Level Referral Center. <i>International Journal of Infectious Diseases</i> , 2019, 80, 105-110.	1.5	3
64	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	2.0	81
65	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
66	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	6.1	290
67	Reflux symptoms in professional opera soloists. <i>Digestive and Liver Disease</i> , 2019, 51, 798-803.	0.4	5
68	Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 183.	1.8	70
69	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. <i>Computers in Biology and Medicine</i> , 2019, 104, 335-338.	3.9	3
70	Current and future targets for faecal microbiota transplantation. <i>Human Microbiome Journal</i> , 2019, 11, 100045.	3.8	7
71	Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 615-615.	0.8	4
72	Clostridium difficile: trend in an Italian Tertiary Care Hospital during fifteen years, 2002-2016. <i>Minerva Medica</i> , 2019, 110, 168-171.	0.3	3

#	ARTICLE	IF	CITATIONS
73	Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. <i>Digestive Diseases</i> , 2018, 36, 184-193.	0.8	27
74	Faecal Microbiota Transplantation as Emerging Treatment in European Countries. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1050, 177-195.	0.8	7
75	Letter by Ianiro et al Regarding Article, "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium": <i>Circulation</i> , 2018, 137, 213-214.	1.6	1
76	Faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2018, 67, 196.2-197.	6.1	18
77	Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. <i>Digestive Diseases</i> , 2018, 36, 56-65.	0.8	146
78	Fecal calprotectin in management of <i>Clostridium difficile</i> infection: a longitudinal study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 567-572.	0.6	8
79	Response to: Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease": <i>Mediators of Inflammation</i> , 2018, 2018, 1-2.	1.4	5
80	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory <i>Clostridium difficile</i> infection: single versus multiple infusions. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 152-159.	1.9	117
81	Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	1.4	62
82	Wheat desensitization treatment in patients with gluten sensitivity. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 320-322.	0.4	2
83	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1232-1244.	1.6	137
84	PC.01.7 RANDOMIZED CLINICAL TRIAL: SINGLE-INFUSION FMT VERSUS MULTIPLE-INFUSION FMT FOR THE TREATMENT OF SEVERE C. DIFFICILE INFECTION. <i>Digestive and Liver Disease</i> , 2018, 50, e66-e67.	0.4	4
85	<i>Bacillus clausii</i> for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2018, 10, 1074.	1.7	62
86	Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond <i>Clostridium difficile</i> infection: an update. <i>Drugs of Today</i> , 2018, 54, 123.	0.7	17
87	<i>Helicobacter pylori</i> in metabolic related diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2018, 64, 297-309.	2.2	11
88	Ipilimumab Adjuvant Therapy in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 398-399.	13.9	7
89	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	6.1	793
90	Predictors of failure after single faecal microbiota transplantation in patients with recurrent <i>Clostridium difficile</i> infection: results from a 3-year cohort study: authors' reply. <i>Clinical Microbiology and Infection</i> , 2017, 23, 891.	2.8	20

#	ARTICLE	IF	CITATIONS
91	Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clinical Microbiology and Infection, 2017, 23, 337.e1-337.e3.	2.8	60
92	Screening of colorectal cancer: present and future. Expert Review of Anticancer Therapy, 2017, 17, 1131-1146.	1.1	123
93	P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?. Digestive and Liver Disease, 2017, 49, e159.	0.4	0
94	P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis. Digestive and Liver Disease, 2017, 49, e158-e159.	0.4	0
95	Gut Microbiota and Cancer Patients: A Broad-Ranging Relationship. Mayo Clinic Proceedings, 2017, 92, 1605-1607.	1.4	7
96	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology, 2017, 174, 1426-1449.	2.7	126
97	Prevention and treatment of Clostridium difficile infection. Geriatric Care, 2017, 3, .	0.2	0
98	Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. Gastroenterology Research and Practice, 2017, 2017, 1-11.	0.7	119
99	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS ONE, 2017, 12, e0186575.	1.1	23
100	Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterology, 2017, 63, 420-430.	0.3	22
101	The gut microbiota: its anatomy and physiology over a lifetime. Minerva Gastroenterology, 2017, 63, 329-336.	0.3	16
102	Digestive Enzyme Supplementation in Gastrointestinal Diseases. Current Drug Metabolism, 2016, 17, 187-193.	0.7	87
103	Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World Journal of Gastroenterology, 2016, 22, 5505.	1.4	141
104	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Digestive Diseases, 2016, 34, 269-278.	0.8	105
105	Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Digestive Diseases, 2016, 34, 279-285.	0.8	22
106	P.12.2 DIAGNOSIS OF CELIAC DISEASE IN ADULTS WITHOUT DUODENAL BIOPSY IN THE PRESENCE OF POSITIVE ANTI-ENDOMYSIUM ANTIBODIES AND ANTI-TRANSGLUTAMINASE ANTIBODIES. Digestive and Liver Disease, 2016, 48, e185.	0.4	0
107	Gut Virome and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1708-1712.	0.9	39
108	Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 983-991.	1.0	18

#	ARTICLE	IF	CITATIONS
109	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. <i>Transplantation Proceedings</i> , 2016, 48, 402-407.	0.3	26
110	Endoscopic evaluation of celiac disease. <i>Endoscopy International Open</i> , 2016, 04, E547-E548.	0.9	0
111	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. <i>Applied and Environmental Microbiology</i> , 2016, 82, 6633-6644.	1.4	85
112	Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. <i>Digestive and Liver Disease</i> , 2016, 48, 1043-1047.	0.4	6
113	The Role of Biomarkers in Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S26-S28.	1.1	19
114	P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?. <i>Digestive and Liver Disease</i> , 2016, 48, e157.	0.4	0
115	P.08.11 THE POSITION WITHIN THE OESOPHAGEAL CIRCUMFERENCE PREDICTS DYSPLASIA IN SHORT SEGMENT BARRETT'S ESOPHAGUS: A 7-YEAR RETROSPECTIVE SERIES OF 341 LESIONS. <i>Digestive and Liver Disease</i> , 2016, 48, e168-e169.	0.4	0
116	OC.12.9 FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT C. DIFFICILE INFECTION: A 2-YEAR EXPERIENCE FROM A EUROPEAN REFERRAL CENTRE. <i>Digestive and Liver Disease</i> , 2016, 48, e118.	0.4	0
117	Real-time diagnosis of <i>H. pylori</i> infection during endoscopy: Accuracy of an innovative tool (EndoFaster). <i>United European Gastroenterology Journal</i> , 2016, 4, 339-342.	1.6	16
118	Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e139.	1.3	19
119	Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1259-1267.	1.4	20
120	Olmesartan-associated sprue-like enteropathy: know your enemy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 891-891.	0.6	1
121	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016, 48, 391-398.	0.4	17
122	Probiotics in prevention and treatment of obesity: a critical view. <i>Nutrition and Metabolism</i> , 2016, 13, 14.	1.3	235
123	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9727.	1.4	5
124	The role of diet on gut microbiota composition. <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 4742-4749.	0.5	149
125	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 835-843.	1.9	467
126	Decrease in Surgery for <i>Clostridium difficile</i> Infection After Starting a Program to Transplant Fecal Microbiota. <i>Annals of Internal Medicine</i> , 2015, 163, 487-488.	2.0	56



#	ARTICLE	IF	CITATIONS
127	Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. <i>Journal of Translational Medicine</i> , 2015, 13, 220.	1.8	10
128	Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1030-1030.	1.9	11
129	Effect of short term aerobic exercise on fasting and postprandial lipoprotein subfractions in healthy sedentary men. <i>Lipids in Health and Disease</i> , 2015, 14, 151.	1.2	10
130	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 149-151.		139
131	Current technologies for the endoscopic assessment of duodenal villous pattern in celiac disease. <i>Computers in Biology and Medicine</i> , 2015, 65, 308-314.	3.9	11
132	Tu1533 Esophageal Posterior and Right Wall Are the Most Common Localizations of Barrett's Esophagus. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB499.	0.5	0
133	Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification. <i>Digestive Diseases</i> , 2015, 33, 68-76.	0.8	62
134	Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection in a Patient with Chronic Refractory Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 367-367.	0.6	5
135	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. <i>Medicine (United States)</i> , 2014, 93, e97.	0.4	77
136	Systematic review: sprue-like enteropathy associated with olmesartan. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 16-23.	1.9	117
137	Letter: telmisartan associated enteropathy "is there any class effect? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 570-570.	1.9	15
138	Letter: faecal microbiota transplantation - not a one-size-fits-all approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 119-119.	1.9	4
139	Fecal Microbiota Transplantation for the Treatment of <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 693-702.	1.1	375
140	Role of Microbiota and Innate Immunity in Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	43
141	Moderately Severe Acute Pancreatitis Associated With Riluzole. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 563.	1.1	12
142	OC.05.5 DEVELOPMENT AND VALIDATION OF AN ENDOSCOPIC CLASSIFICATION OF DIVERTICULAR DISEASE OF THE COLON: THE DICA CLASSIFICATION. <i>Digestive and Liver Disease</i> , 2014, 46, S14-S15.	0.4	1
143	OC.11.3 MUCOSAL HEALING DOES NOT CORRESPOND TO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS. <i>Digestive and Liver Disease</i> , 2014, 46, S26-S27.	0.4	0
144	P090 Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S99-S100.	0.6	1

#	ARTICLE	IF	CITATIONS
145	OC.13.4 MULTIPARAMETRIC EVALUATION OF CROHN'S DISEASE: INTESTINAL HEALING BEYOND MUCOSAL HEALING. <i>Digestive and Liver Disease</i> , 2014, 46, S31.	0.4	0
146	P182 Multiparametric evaluation of Crohn's disease: possible role of intestinal healing beyond mucosal healing. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S138.	0.6	0
147	OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION. <i>Digestive and Liver Disease</i> , 2014, 46, S35.	0.4	0
148	P184 Mucosal healing does not correspond to histological healing in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S139.	0.6	0
149	Dramatic improvement of parkinsonian symptoms after gluten-free diet introduction in a patient with silent celiac disease. <i>Journal of Neurology</i> , 2014, 261, 443-445.	1.8	11
150	Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. <i>Internal and Emergency Medicine</i> , 2014, 9, 365-373.	1.0	98
151	Nickel Free-Diet Enhances the <i>Helicobacter pylori</i> Eradication Rate: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1851-1855.	1.1	30
152	P.18.4 EFFICACY OF ANTIOXIDANT THERAPY IN IMPROVING PAINFUL CHRONIC PANCREATITIS: A SYSTEMATIC REVIEW. <i>Digestive and Liver Disease</i> , 2014, 46, S128.	0.4	0
153	P.15.1 PROSPECTIVE VALIDATION OF ENDOFASTER FOR A REALTIME DIAGNOSIS OF H. PYLORI INFECTION DURING UPPER ENDOSCOPY. <i>Digestive and Liver Disease</i> , 2014, 46, S111.	0.4	0
154	P.06.9 INFLIXIMAB IS NOT INCREASING COLONIC CANCER RISK ASSOCIATED TO CHRONIC COLITIS IN MICE. <i>Digestive and Liver Disease</i> , 2014, 46, S73.	0.4	0
155	P.17.13 WHITE MULBERRY SUPPLEMENTATION AS ADJUVANT TREATMENT OF OBESITY. <i>Digestive and Liver Disease</i> , 2014, 46, S124.	0.4	1
156	Faecal transplantation for <i>Clostridium difficile</i> infection. Three cases treated in Italy. <i>Digestive and Liver Disease</i> , 2014, 46, 475.	0.4	6
157	Fecal Microbiota Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S80-S84.	1.1	33
158	Role of Yeasts in Healthy and Impaired Gut Microbiota: The Gut Mycome. <i>Current Pharmaceutical Design</i> , 2014, 20, 4565-4569.	0.9	51
159	Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives. <i>Current Drug Targets</i> , 2014, 15, 762-770.	1.0	74
160	Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 5205.	1.4	38
161	Image-Enhanced Endoscopy with I-scan Technology for the Evaluation of Duodenal Villous Patterns. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1287-1292.	1.1	26
162	Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice. <i>Digestive and Liver Disease</i> , 2013, 45, 1017-1021.	0.4	38

#	ARTICLE	IF	CITATIONS
163	The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response. Cytokine and Growth Factor Reviews, 2013, 24, 455-466.	3.2	50
164	Pre- and Posttherapy Assessment of Intestinal Soluble Mediators in IBD: Where We Stand and Future Perspectives. Mediators of Inflammation, 2013, 2013, 1-9.	1.4	5
165	Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. BioMed Research International, 2013, 2013, 1-9.	0.9	156
166	Endoscopic tools for the diagnosis and evaluation of celiac disease. World Journal of Gastroenterology, 2013, 19, 8562.	1.4	32
167	Gluten-related recurrent peripheral facial palsy: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 667-668.	0.9	6
168	Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal Immune Niche in Coeliac Disease After Gluten-Free Diet. Clinical and Translational Gastroenterology, 2012, 3, e28.	1.3	25
169	Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Digestive and Liver Disease, 2012, 44, 1032-1036.	0.4	16
170	Review article: biofilm formation by <i>Helicobacter pylori</i> as a target for eradication of resistant infection. Alimentary Pharmacology and Therapeutics, 2012, 36, 222-230.	1.9	84
171	Microscopic colitis. World Journal of Gastroenterology, 2012, 18, 6206.	1.4	40
172	New insights on the role of T cells in the pathogenesis of celiac disease. Journal of Biological Regulators and Homeostatic Agents, 2012, 26, 171-9.	0.7	14
173	I-Scan Technology is Useful to Improve the Rate of Gastric Varices Diagnosis in Patients With Portal Hypertension. Gastroenterology, 2011, 140, S-753.	0.6	0
174	P.1.38: SEQUENTIAL AND STANDARD LEVOFLOXACIN-BASED H. PYLORI ERADICATING REGIMENS COMPARED TO QUADRUPLE THERAPY: EFFECT OF LEVOFLOXACIN DOSAGE AND WAY OF ADMINISTRATION. Digestive and Liver Disease, 2011, 43, S160-S161.	0.4	0
175	P.1.57: LGR5+ INTESTINAL STEM CELLS INVOLVEMENT IN EPITHELIAL REGENERATION FOLLOWING GLUTEN FREE DIET IN CELIAC PATIENTS. Digestive and Liver Disease, 2011, 43, S167.	0.4	0
176	P.1.303: HIGH DOSE AMOXICILLIN-BASED FIRST LINE REGIMEN IS EQUIVALENT TO SEQUENTIAL THERAPY IN THE ERADICATION OF H. PYLORI INFECTION. Digestive and Liver Disease, 2011, 43, S248-S249.	0.4	0
177	Combined atherogenic effects of celiac disease and type 1 diabetes mellitus. Atherosclerosis, 2011, 217, 531-535.	0.4	48
178	Spectral Endoscopic Imaging. Journal of Clinical Gastroenterology, 2011, 45, 6-15.	1.1	18
179	Lactose Intolerance in Systemic Nickel Allergy Syndrome. International Journal of Immunopathology and Pharmacology, 2011, 24, 535-537.	1.0	10
180	Gastrointestinal: An unusual gastric flat lesion: amyloidosis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 784-784.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Alcohol and Alcoholism</i> , 2011, 46, 312-317.	0.9	173
182	Reflux symptoms in wind instrument players. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 593-600.	1.9	11
183	The combined application of advanced endoscopic imaging techniques may increase the duodenal villous morphology definition in suspected celiac disease. <i>Digestive and Liver Disease</i> , 2010, 42, 595-596.	0.4	2
184	OC.06.3 METABOLIC SYNDROME PROMOTES THE OCCURRENCE OF PRE-NEOPASTIC LESIONS OF THE COLONIC MUCOSA. <i>Digestive and Liver Disease</i> , 2010, 42, S84.	0.4	0
185	OC.09.1 DYNAMICS OF INTESTINAL REGENERATION FOLLOWING GLUTEN-FREE DIET IN CELIAC PATIENTS AND ROLE OF CIRCULATING HEMATOPOIETIC STEM CELLS. <i>Digestive and Liver Disease</i> , 2010, 42, S91.	0.4	0
186	Tired legs – a gut diagnosis. <i>Lancet</i> , The, 2010, 376, 1798.	6.3	7
187	Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant <i>Helicobacter pylori</i> : A Clinical Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 817-820.e3.	2.4	79
188	Can chronic gastritis cause an increase in fecal calprotectin concentrations?. <i>World Journal of Gastroenterology</i> , 2010, 16, 3406.	1.4	19
189	Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity. <i>Annals of Clinical and Laboratory Science</i> , 2010, 40, 3-9.	0.2	21
190	Celiac Disease in the 21st Century: Issues of Under-and Over-Diagnosis. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 1-7.	1.0	21
191	Emerging technologies in upper gastrointestinal endoscopy and celiac disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2009, 6, 47-56.	1.7	41
192	The Interaction Between Small Intestinal Bacterial Overgrowth and Warfarin Treatment. <i>American Journal of Gastroenterology</i> , 2009, 104, 2364-2365.	0.2	7
193	Involvement of central immunity in uncomplicated diverticular disease. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 108-115.	0.6	32
194	Cellular Mediators of Inflammation: Tregs and $T_H$ 17 Cells in Gastrointestinal Diseases. <i>Mediators of Inflammation</i> , 2009, 2009, 1-11.	1.4	28
195	Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009, 49, 1877-1887.	3.6	1,138
196	T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. <i>Clinical and Experimental Immunology</i> , 2009, 158, 106-114.	1.1	22
197	Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment. <i>Human Immunology</i> , 2009, 70, 430-435.	1.2	35
198	CYCLIC TREATMENT WITH MESALAZINE IN PREVENTING RECURRENCE OF SMALL INTESTINAL BACTERIAL OVERGROWTH AFTER ANTIBIOTIC TREATMENT. <i>Digestive and Liver Disease</i> , 2009, 41, S67.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Free Peritoneal Gas Accumulation Caused by Pneumatosis Coli After Diagnostic Gastrointestinal Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, A18.	2.4	2
200	Patchy Left-Sided Colitis: Primary Eosinophilic Colitis or Paraneoplastic Syndrome?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, e61.	2.4	1
201	Water Immersion Technique During Standard Upper Endoscopy May Be Useful to Drive the Biopsy Sampling of Duodenal Mucosa in Children With Celiac Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 49, 411-416.	0.9	26
202	The Water Immersion Technique is Easy to Learn for Routine Use During EGD for Duodenal Villous Evaluation. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 244-248.	1.1	33
203	Quick Test: A New Test for the Diagnosis of Duodenal Hypolactasia. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1589-1592.	1.1	15
204	Increased Frequency of Ig Heavy-Chain HS1,2-A Enhancer *2 Allele in Dermatitis Herpetiformis, Plaque Psoriasis, and Psoriatic Arthritis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1920-1924.	0.3	34
205	Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1003-1012.	1.9	54
206	OC3.08.2 SMALL INTESTINAL BACTERIAL OVERGROWTH IN A CHILDREN POPULATION AFFECTED BY IRRITABLE BOWEL SYNDROME: A CASE-CONTROL STUDY. <i>Digestive and Liver Disease</i> , 2008, 40, S59.	0.4	0
207	OC3.09.2 EFFECT OF LACTOSE AMOUNT PRESENT IN DRUGS ON H2 EXCRETION AND GASTROINTESTINAL SYMPTOMS. <i>Digestive and Liver Disease</i> , 2008, 40, S62-S63.	0.4	0
208	PA.10 ROLE OF VIRTUAL CHROMO-ENDOSCOPY (CVC) FOR DETECTION OF PATIENTS WITH COMPLICATED GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD): A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2008, 40, S79.	0.4	0
209	PA.29 IMPACT OF L. REUTERII SUPPLEMENTATION ON ANTI-H. PYLORI SECOND LINE THERAPY-RELATED. <i>Digestive and Liver Disease</i> , 2008, 40, S86.	0.4	0
210	PA.49 LACTOSE MALABSORPTION IN PATIENTS AFFECTED BY RECURRENT VAGINITIS. <i>Digestive and Liver Disease</i> , 2008, 40, S93.	0.4	0
211	PA.53 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) IN PATIENTS WITH DUODENOGASTRIC REFLUX (DGR) POST-CHOLECYSTECTOMY. <i>Digestive and Liver Disease</i> , 2008, 40, S94-S95.	0.4	0
212	PA.55 SMALL INTESTINAL BACTERIAL OVERGROWTH RECURRENCE AFTER ANTIBIOTIC THERAPY. <i>Digestive and Liver Disease</i> , 2008, 40, S95.	0.4	0
213	PA.58 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) CAN AFFECT INTESTINAL PERMEABILITY. <i>Digestive and Liver Disease</i> , 2008, 40, S96.	0.4	0
214	PA.194 VALUE OF THE WATER-IMMERSION TECHNIQUE DURING UPPER ENDOSCOPY IN EVALUATING DUODENAL VILLOUS ATROPHY IN CELIAC CHILDREN. <i>Digestive and Liver Disease</i> , 2008, 40, S146-S147.	0.4	0
215	PA.248 MAGNIFICATION WITH VIRTUAL CHROMO-ENDOSCOPY (CVC) IN THE EVALUATION OF COLORECTAL MUCOSAL LESIONS: A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2008, 40, S166.	0.4	0
216	PO.13 RIFAXIMIN VERSUS METRONIDAZOLE FOR THE TREATMENT OF SMALL BOWEL BACTERIAL OVERGROWTH. <i>Digestive and Liver Disease</i> , 2008, 40, S175.	0.4	1

#	ARTICLE	IF	CITATIONS
217	Optimal band imaging system: a new tool for enhancing the duodenal villous pattern in celiac disease. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 352-357.	0.5	30
218	Skeletal muscle wastage in Crohn's disease: A pathway shared with heart failure?. <i>International Journal of Cardiology</i> , 2008, 127, 219-227.	0.8	35
219	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. <i>Human Immunology</i> , 2008, 69, 837-839.	1.2	27
220	Fecal Calprotectin Concentrations in Patients with Small Intestinal Bacterial Overgrowth. <i>Digestive Diseases</i> , 2008, 26, 183-186.	0.8	26
221	Adverse Reactions to Food: Allergies and Intolerances. <i>Digestive Diseases</i> , 2008, 26, 96-103.	0.8	24
222	Classification of Malabsorption Syndromes. <i>Digestive Diseases</i> , 2008, 26, 104-111.	0.8	13
223	Celiac Disease: What's New about It?. <i>Digestive Diseases</i> , 2008, 26, 121-127.	0.8	24
224	Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy. <i>American Journal of Gastroenterology</i> , 2008, 103, 2031-2035.	0.2	112
225	Reply to Souza et al.. <i>Endoscopy</i> , 2008, 40, 621-621.	1.0	0
226	Abnormal synthesis of IgA in coeliac disease and related disorders. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2008, 22, 99-104.	0.7	5
227	Faecal calprotectin concentrations in untreated coeliac patients. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 957-961.	0.6	39
228	Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4180-4184.	1.8	108
229	Fecal Calprotectin in First-Degree Relatives of Patients with Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 132-136.	0.2	29
230	A highly accurate method for monitoring histological recovery in patients with celiac disease on a gluten-free diet using an endoscopic approach that avoids the need for biopsy: a double-center study. <i>Endoscopy</i> , 2007, 39, 46-51.	1.0	41
231	Reply to K. Rostami et al.. <i>Endoscopy</i> , 2007, 39, 574-574.	1.0	1
232	Hydrogen peroxide-related colitis (previously known as "pseudolipomatosis"): a series of cases occurring in an epidemic pattern. <i>Endoscopy</i> , 2007, 39, 916-919.	1.0	16
233	Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 1026-1030.	0.8	11
234	Bile Acids and Total Bilirubin Detection in Saliva of Patients Submitted to Gastric Surgery and in Particular to Subtotal Billroth II Resection. <i>Annals of Surgery</i> , 2007, 245, 880-885.	2.1	23

#	ARTICLE	IF	CITATIONS
235	Role of the "Immersion Technique" in Diagnosing Celiac Disease With Villous Atrophy Limited to the Duodenal Bulb. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 571-575.	1.1	27
236	Fecal calprotectin in first degree relatives of patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 669.	0.9	0
237	Reflux Symptoms in Professional Opera Choristers. <i>Gastroenterology</i> , 2007, 132, 890-898.	0.6	60
238	Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. <i>Digestive and Liver Disease</i> , 2007, 39, 483-487.	0.4	57
239	Accuracy and Learning Curve and of the Water-Immersion Technique in Assessing Marked Villous Atrophy of the Duodenum: A Single Centre 4-Year Experience. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB339.	0.5	1
240	Role of the Fujinon Intelligent Chromo Endoscopy (FICE) for Detection of Patients with Suspected Celiac Disease (CD): A Pilot Study. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB356.	0.5	0
241	High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 781-786.	1.9	94
242	Increased prevalence of small intestinal bacterial overgrowth in patients with non-erosive reflux disease (NERD). <i>Digestive and Liver Disease</i> , 2006, 38, S81.	0.4	0
243	A case-control study comparing methylene blue directed biopsies and random biopsies for detecting pre-cancerous lesions in the follow-up of gastric cancer patients. <i>Digestive and Liver Disease</i> , 2006, 38, S149.	0.4	1
244	Duodenal metastasis from a primary angiosarcoma of the colon. <i>Gastrointestinal Endoscopy</i> , 2006, 63, 330.	0.5	10
245	Virulent strains of <i>Helicobacter pylori</i> and vascular diseases: A meta-analysis. <i>American Heart Journal</i> , 2006, 151, 1215-1222.	1.2	60
246	Management and treatment of lactose malabsorption. <i>World Journal of Gastroenterology</i> , 2006, 12, 187.	1.4	159
247	Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 965-967.	0.8	21
248	Biliary laryngopharyngeal reflux: a new pathological entity. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006, 14, 128-132.	0.8	34
249	High accuracy and cost-effectiveness of a biopsy-avoiding endoscopic approach in diagnosing coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 61-69.	1.9	38
250	A higher diagnostic profile is possible for microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 561-561.	1.9	2
251	Rifaximin-Based Regimens for Eradication of <i>Helicobacter pylori</i> : A Pilot Study. <i>Digestive Diseases</i> , 2006, 24, 195-200.	0.8	25
252	Accuracy of Laryngeal Examination during Upper Gastrointestinal Endoscopy for Premalignancy Screening: Prospective Study in Patients with and without Reflux Symptoms. <i>Endoscopy</i> , 2006, 38, 376-381.	1.0	14

#	ARTICLE	IF	CITATIONS
253	Preliminary Laryngeal Examination During Magnifying Upper Gastrointestinal Video Endoscopy in Two Patients with Reflux Symptoms. <i>Endoscopy</i> , 2006, 38, 287-287.	1.0	3
254	Rapid detection of clarithromycin resistance in <i>Helicobacter pylori</i> using a PCR-based denaturing HPLC assay. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 71-78.	1.3	22
255	Levofloxacin-Based Triple Therapy in First-Line Treatment for <i>Helicobacter pylori</i> Eradication. <i>American Journal of Gastroenterology</i> , 2006, 101, 1985-1990.	0.2	67
256	Third-line rescue therapy for <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2006, 12, 2313.	1.4	39
257	Laryngeal carcinoma and laryngo-pharyngeal reflux disease. <i>Acta Otorhinolaryngologica Italica</i> , 2006, 26, 260-3.	0.7	24
258	An Attempt of Specific Desensitising Treatment with Gliadin in Celiac Disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 709-714.	1.0	4
259	Moxifloxacin-based strategies for first-line treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1241-1247.	1.9	61
260	Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1391-1395.	1.9	174
261	Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 31-35.	1.9	102
262	Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1157-1160.	1.9	161
263	High-Resolution Magnifying Upper Endoscopy in a Patient with Patchy Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 601-604.	1.1	11
264	Corkscrew Esophagus. <i>New England Journal of Medicine</i> , 2005, 352, 816-816.	13.9	2
265	High-Resolution Magnifying Video Endoscopy in Primary Intestinal Lymphangiectasia: a New Role for Endoscopy?. <i>Endoscopy</i> , 2005, 37, 607-607.	1.0	15
266	Double-balloon enteroscopy for diagnosis of a Meckel's diverticulum in a patient with GI bleeding of obscure origin. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 779-781.	0.5	29
267	No more biopsy in the diagnostic work-up of celiac disease. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 119-121.	0.5	10
268	High Prevalence of Celiac Disease in Patients with Lactose Intolerance. <i>Digestion</i> , 2005, 71, 106-110.	1.2	77
269	Regression of E12-stage low-grade gastric MALT-lymphoma after <i>H. pylori</i> eradication. <i>Hepato-Gastroenterology</i> , 2005, 52, 975-7.	0.5	1
270	High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 789-795.	1.9	98



#	ARTICLE	IF	CITATIONS
271	Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1181-1188.	1.9	156
272	Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. <i>American Journal of Cardiology</i> , 2004, 94, 40-44.	0.7	71
273	High Prevalence of Hyperplastic Colonic Polyps in Acromegalic Subjects. <i>Digestive Diseases and Sciences</i> , 2004, 49, 662-666.	1.1	13
274	CASE REPORT: Celiac Disease and Chronic Urticaria Resolution: A Case Report. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1489-1490.	1.1	5
275	Increased frequency of the immunoglobulin enhancer HS1,2 allele 2 in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 1083-1087.	0.6	38
276	High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against <i>Helicobacter pylori</i> isolates from patients after failure of therapy. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 433-438.	1.1	38
277	Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 223-228.	0.5	46
278	Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 732-738.	0.5	72
279	Association of Laryngeal Cancer With Previous Gastric Resection. <i>Annals of Surgery</i> , 2004, 240, 817-824.	2.1	25
280	<i>Helicobacter pylori</i> Eradication Rate and Glycemic Control in Young Patients With Type 1 Diabetes. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 38, 422-425.	0.9	23
281	High-dose Versus Low-dose Clarithromycin in 1-week Triple Therapy, Including Rabeprazole and Levofloxacin, for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 110-114.	1.1	18
282	<i>Helicobacter pylori</i> and gastro-oesophageal reflux disease: Information on underlying pathology is not given. <i>BMJ: British Medical Journal</i> , 2004, 329, 402.1.	2.4	1
283	Levofloxacin-based triple therapy vs. quadruple therapy in second-line <i>Helicobacter pylori</i> treatment: a randomized trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 627-633.	1.9	95
284	10 days levofloxacin-based triple therapy in second-line treatment for <i>Helicobacter pylori</i> eradication. <i>Gastroenterology</i> , 2003, 124, A359.	0.6	3
285	First-line treatment for <i>Helicobacter pylori</i> eradication: New moxifloxacin-based strategies. <i>Gastroenterology</i> , 2003, 124, A359.	0.6	0
286	Impact of bacillus clausii supplementation on anti <i>Helicobacter pylori</i> therapy related side effects: A randomized double blind placebo controlled study. <i>Gastroenterology</i> , 2003, 124, A361.	0.6	0
287	Post-cholecystectomy Alkaline Reactive Gastritis: A randomized trial comparing sucralfate versus rabeprazole or no treatment. <i>Gastroenterology</i> , 2003, 124, A456.	0.6	1
288	Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 348-351.	0.5	64

#	ARTICLE	IF	CITATIONS
289	Post-cholecystectomy alkaline reactive gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 975-979.	0.8	18
290	Worsening of Gastroesophageal Reflux Symptoms in Professional Singers During Performances. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 403-404.	1.1	12
291	Gastric Surgery as a Long-term Risk Factor for Malignant Lesions of the Larynx. <i>Archives of Surgery</i> , 2003, 138, 751.	2.3	13
292	Bile reflux as possible risk factor in laryngopharyngeal inflammatory and neoplastic lesions. <i>Acta Otorhinolaryngologica Italica</i> , 2003, 23, 377-82.	0.7	25
293	Levofloxacin based regimens for the eradication of <i>Helicobacter pylori</i> . <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1309-1312.	0.8	62
294	Relationship Between Gastric Localization of Hepatitis C Virus and Mucosa-associated Lymphoid Tissue in <i>Helicobacter pylori</i> Infection. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 1126-1132.	0.6	6
295	Mono, dual and triple moxifloxacin-based therapies for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 527-532.	1.9	47
296	The Role of Acid and Alkaline Reflux in Laryngeal Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2002, 112, 1861-1865.	1.1	91
297	Effect of different probiotic preparations on anti- <i>Helicobacter pylori</i> therapy-related side effects: a parallel group, triple blind, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2002, 97, 2744-2749.	0.2	299
298	EUS in the diagnosis of collagenous colitis. <i>Gastrointestinal Endoscopy</i> , 2001, 54, 113-115.	0.5	6
299	Relationship between gastric localization of HCV and gastric, <i>H. pylori</i> -related lymphoid tissue. <i>Journal of Hepatology</i> , 2001, 34, 130.	1.8	0
300	Relationship between gastric localization of hepatitis C virus and gastric mucosa-associated lymphoid tissue related to <i>Helicobacter pylori</i> infection. <i>Gastroenterology</i> , 2001, 120, A746-A747.	0.6	0
301	Link Between <i>Helicobacter pylori</i> Infection and Iron-Deficiency Anaemia in Patients with Coeliac Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 1284-1288.	0.6	26
302	Prevalence of and risk factors for <i>Helicobacter pylori</i> infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 185-189.	0.8	13
303	The effect of oral administration of <i>Lactobacillus GG</i> on antibiotic-associated gastrointestinal side-effects during <i>Helicobacter pylori</i> eradication therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 163-169.	1.9	245
304	Effect of <i>Lactobacillus GG</i> Supplementation on Antibiotic-Associated Gastrointestinal Side Effects during <i>Helicobacter pylori</i> Eradication Therapy: A Pilot Study. <i>Digestion</i> , 2001, 63, 1-7.	1.2	155
305	Benign and malignant laryngeal lesions in patients with different type of surgical resection of the stomach. <i>Gastroenterology</i> , 2001, 120, A423-A423.	0.6	0
306	Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with <i>H. pylori</i> infection. Could the two neoplasms share a common pathogenesis?. <i>Hepato-Gastroenterology</i> , 2001, 48, 104-6.	0.5	7

#	ARTICLE	IF	CITATIONS
307	Helicobacter pylori Eradication and Remission of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 169-171.	1.1	36
308	Is there an antigenic mimicry between arteriosclerotic lesions and H. pylori antigens?. <i>Clinical Biochemistry</i> , 2000, 33, 419-421.	0.8	6
309	Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxicillin or tinidazole for Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 73-77.	1.9	16
310	Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1339-1343.	1.9	146
311	A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1625-1629.	1.9	204
312	Celiac disease and autoimmune endocrine disorders. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1470-1471.	1.1	1
313	Is the alkaline reflux a risk factor for laryngeal lesions?. <i>American Journal of Gastroenterology</i> , 2000, 95, 2398-2398.	0.2	12
314	Gastric Mucosal Lesions in Celiac Patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 1364-1365.	0.2	1
315	Is there any relationship between IEL and lymphoid follicles in the gastric mucosa? Reply. <i>Gut</i> , 2000, 47, 314-315.	6.1	0
316	Helicobacter pylori infection and autoimmune pathogenesis of gastric neoplasias. <i>Gut</i> , 2000, 46, 293d-293.	6.1	4
317	Onset of coeliac disease during treatment with interferon for chronic hepatitis C. <i>Lancet, The</i> , 2000, 356, 1494-1495.	6.3	118
318	Factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. <i>Gastroenterology</i> , 2000, 118, A1363.	0.6	0
319	Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case against. <i>Digestive and Liver Disease</i> , 2000, 32, 65-68.	0.4	17
320	Long-term omeprazole treatment and risk of gastric cancer. <i>Gastroenterology</i> , 2000, 119, 1176-1177.	0.6	2
321	Role of sucralfate in gastrointestinal diseases. <i>Panminerva Medica</i> , 2000, 42, 55-9.	0.2	11
322	Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection. <i>Hepato-Gastroenterology</i> , 2000, 47, 1176-9.	0.5	0
323	Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2386-2389.	1.1	6
324	Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 247-250.	0.8	15

#	ARTICLE	IF	CITATIONS
325	Insulin-dependent diabetes mellitus affects eradication rate of <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 713-716.	0.8	33
326	Eradication of <i>Helicobacter pylori</i> in routine clinical practice: doubts and uncertainties. <i>Hepato-Gastroenterology</i> , 1999, 46, 312-5.	0.5	1
327	Minimal endoscopic aspects of gastric low-grade malt-lymphoma. <i>Hepato-Gastroenterology</i> , 1999, 46, 2818-22.	0.5	1
328	One-week therapy for <i>Helicobacter pylori</i> eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 539-543.	1.9	13
329	<i>Helicobacter pylori</i> infection and idiopathic arrhythmias. <i>Gastroenterology</i> , 1998, 114, A123.	0.6	0
330	Regression of autoimmune thrombocytopenic purpura after <i>Helicobacter pylori</i> eradication. <i>Gastroenterology</i> , 1998, 114, A124.	0.6	4
331	Role of <i>Helicobacter pylori</i> infection in dyspepsia. <i>Gastroenterology</i> , 1998, 114, A130.	0.6	0
332	Variation of the endoscopic pattern of low-grade gastric malt-lymphoma after <i>Helicobacter pylori</i> eradication. <i>Gastrointestinal Endoscopy</i> , 1998, 48, 231-232.	0.5	5
333	Disappearance of Gastric Mucosa-Associated Lymphoid Tissue in Coeliac Patients after Gluten Withdrawal. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 401-405.	0.6	25
334	Association of Virulent <i>Helicobacter pylori</i> Strains With Ischemic Heart Disease. <i>Circulation</i> , 1998, 97, 1675-1679.	1.6	299
335	Oxatomide in Food Allergies. Comparative Study versus Disodium Chromoglycate. <i>International Journal of Immunopathology and Pharmacology</i> , 1998, 11, 149-154.	1.0	3
336	<i>Helicobacter pylori</i> infection and ischaemic heart disease. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1998, 30 Suppl 3, S304-6.	0.5	3
337	What is the best azithromycin-based therapy for <i>Helicobacter pylori</i> infection?. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 111-111.	1.3	1
338	Endoscopic findings and clinical patterns are not useful for distinguishing low from high grade gastric MALT lymphoma. Reply. <i>Gut</i> , 1997, 41, 577-577.	6.1	3
339	Gastric Mucosa-Associated Lymphoid Tissue in Autoimmune Thyroid Diseases. <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 869-872.	0.6	27
340	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	0.6	27
341	1.P.303 A new human atrial natriuretic peptide gene C/T polymorphism is more frequent in type 1 microalbuminuric diabetic patients. <i>Atherosclerosis</i> , 1997, 134, 81.	0.4	0
342	Pathogenesis of MALT lymphoma: An antigen-dependent process. <i>Gastroenterology</i> , 1997, 113, 1810.	0.6	9

#	ARTICLE	IF	CITATIONS
343	CD4-Mediated Anchoring of the Seminal Antigen gp17 onto the Spermatozoon Surface. <i>Human Immunology</i> , 1997, 58, 30-41.	1.2	30
344	Editorial: The Role of Endoscopy in the Diagnosis and Follow-up of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 496-498.	1.1	5
345	Regression of a primary gastric MALT lymphoma with extensive antrum lesions by <i>Helicobacter pylori</i> eradication. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1997, 29, 361-4.	0.5	3
346	Coeliac disease and follicular gastritis. <i>Lancet, The</i> , 1996, 347, 268.	6.3	20
347	Eradication of <i>Helicobacter pylori</i> as the first step in the treatment of peptic stenosis. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 757.	0.5	1
348	<i>Helicobacter pylori</i> eradication using one-week low-dose lansoprazole plus amoxicillin and either clarithromycin or azithromycin. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 997-1000.	1.9	32
349	Low-dose omeprazole plus clarithromycin and either tinidazole or amoxicillin for <i>Helicobacter pylori</i> infection.. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 285-288.	1.9	27
350	Association of <i>Helicobacter pylori</i> infection, lymphoid follicles, and lymphocytic gastritis: a risk factor for the development of primary gastric lymphoma?. <i>Gut</i> , 1996, 38, 792-792.	6.1	4
351	Role of Dental Plaque in the Transmission of <i>Helicobacter Pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 174-177.	1.1	65
352	<i>Helicobacter Pylori</i> Eradication Helps Resolve Pyloric and Duodenal Stenosis. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 157-158.	1.1	26
353	Prevention and Treatment of Low-grade B-cell Primary Gastric Lymphoma by Anti-H. <i>Pylori</i> Therapy. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 118-122.	1.1	53
354	A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. <i>European Journal of Immunology</i> , 1995, 25, 1461-1464.	1.6	58
355	Omeprazole versus ranitidine in the prevention of duodenal ulcer recurrence after eradication therapy. <i>Current Therapeutic Research</i> , 1995, 56, 568-572.	0.5	1
356	Effect of anti- <i>Helicobacter pylori</i> therapy on inflammatory cell infiltration and acquired malt in gastric mucosa: A morphometric study by means of computer-assisted image analysis. <i>Gastroenterology</i> , 1995, 108, A48.	0.6	0
357	Disappearance of gastric acquired malt and regression of low-grade B-cell gastric lymphoma by means anti-H. <i>pylori</i> treatment. <i>Gastroenterology</i> , 1995, 108, A65.	0.6	0
358	<i>Helicobacter pylori</i> reinfection and rapid relapse of low-grade B-cell gastric lymphoma. <i>Lancet, The</i> , 1995, 345, 192.	6.3	47
359	Partial nucleotide sequencing of six subtype 2c hepatitis C viruses detected in Italy. <i>Journal of Clinical Microbiology</i> , 1995, 33, 2781-2784.	1.8	30
360	A fungal metabolite which inhibits the interaction of CD4 with major histocompatibility complex-encoded class II molecules. <i>European Journal of Immunology</i> , 1994, 24, 991-998.	1.6	8

#	ARTICLE	IF	CITATIONS
361	Helicobacter pylori and the Anatomoclinical Spectrum of Duodenal Ulcer Disease. Journal of Clinical Gastroenterology, 1994, 18, 239.	1.1	0
362	Identification of a CD4 binding site on the $\beta$ 2 domain of HLA-DR molecules. Nature, 1992, 356, 799-801.	13.7	277